keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant chemotherapy in breast cancer

keyword
https://www.readbyqxmd.com/read/28639030/utilization-of-hypofractionated-whole-breast-radiation-therapy-in-patients-receiving-chemotherapy-a-national-cancer-database-analysis
#1
Tejan P Diwanji, Jason K Molitoris, Arpit M Chhabra, James W Snider, Soren M Bentzen, Katherine H Tkaczuk, Paula Y Rosenblatt, Susan B Kesmodel, Emily C Bellavance, Randi J Cohen, Sally B Cheston, Elizabeth M Nichols, Steven J Feigenberg
PURPOSE: Results from four major hypofractionated whole-breast radiotherapy (HF-WBRT) trials have demonstrated equivalence in select patients with early-stage breast cancer when compared with conventionally fractionated WBRT (CF-WBRT). Because relatively little data were available on patients receiving neoadjuvant or adjuvant chemotherapy, consensus guidelines published in 2011 did not endorse the use of HF-WBRT in this population. Our goal is to evaluate trends in utilization of HF-WBRT in patients receiving chemotherapy...
June 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28635235/-the-role-of-postmastectomy-radiotherapy-in-clinical-t1-3n1m0-breast-cancer-patients-with-pathological-negative-lymph-nodes-after-neoadjuvant-chemotherapy-and-mastectomy
#2
Q L Rong, S L Wang, Y Tang, J Jin, Y W Song, W H Wang, Y P Liu, H Fang, H Ren, X F Liu, Z H Yu, Y X Li
Objective: To analyze the outcomes of clinical T1-3N1M0 breast cancer patients with pathological negative axillary lymph nodes (ypN0) after neoadjuvant chemotherapy (NAC) and mastectomy, and investigate the role of postmastectomy radiotherapy (PMRT). Methods: A total of 185 patients with clinical T1-3N1M0 breast cancer treated between 1999 and 2013 were retrospectively reviewed. All patients were treated with NAC and mastectomy, and achieved ypN0. Of them, 89 patients received additional PMRT and 96 patients did not...
June 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28627463/pre-operative-assessment-of-residual-disease-in-locally-advanced-breast-cancer-patients-a-sequential-study-by-quantitative-diffusion-weighted-mri-as-a-function-of-therapy
#3
Khushbu Agarwal, Uma Sharma, Rani G Sah, Sandeep Mathur, Smriti Hari, Vurthaluru Seenu, Rajinder Parshad, Naranamangalam R Jagannathan
PURPOSE: The potential of diffusion weighted imaging (DWI) in assessing pathologic response and surgical margins in locally advanced breast cancer patients (n=38) undergoing neoadjuvant chemotherapy was investigated. METHODS: DWI was performed at pre-therapy (Tp0), after I (Tp1) and III (Tp3) NACT at 1.5T. Apparent diffusion coefficient (ADC) of whole tumor (ADCWT), solid tumor (ADCST), intra-tumoral necrosis (ADCNec) was determined. Further, ADC of 6 consecutive shells (5mm thickness each) including tumor margin to outside tumor margins (OM1 to OM5) was calculated and the data analyzed to define surgical margins...
June 13, 2017: Magnetic Resonance Imaging
https://www.readbyqxmd.com/read/28621239/a-microrna-signature-associated-with-pathological-complete-response-to-novel-neoadjuvant-therapy-regimen-in-triple-negative-breast-cancer
#4
Raúl García-Vazquez, Erika Ruiz-García, Abelardo Meneses García, Horacio Astudillo-de la Vega, Fernando Lara-Medina, Alberto Alvarado-Miranda, Héctor Maldonado-Martínez, Juan A González-Barrios, Alma D Campos-Parra, Sergio Rodríguez Cuevas, Laurence A Marchat, César López-Camarillo
Neoadjuvant chemotherapy aims to improve the outcome of breast cancer patients, but only few would benefit from this treatment. Pathological complete response has been proposed as a surrogate marker for the prediction of long-term clinical benefits; however, 50%-85% patients have an unfavorable pathological complete response to chemotherapy. MicroRNAs are known biomarkers of breast cancer progression; nevertheless, their potential to identify patients with pathological complete response remains poorly understood...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28621233/plasma-fibrinogen-level-may-be-a-possible-marker-for-the-clinical-response-and-prognosis-of-patients-with-breast-cancer-receiving-neoadjuvant-chemotherapy
#5
Yu Mei, Haixia Liu, Xiaorong Sun, Xiangyi Li, Song Zhao, Rong Ma
Neoadjuvant chemotherapy has been established as standard treatments for advanced breast cancer among multidisciplinary therapies. A simple and instructive biomarker for the postoperative recurrence and metastasis is needed to evaluate the therapeutic effect. Plasma fibrinogen level has been shown to be associated with tumor progression and poor outcomes in breast cancer patients. This study aims to further evaluate the clinical and prognostic value of plasma fibrinogen level as a biomarker in breast cancer patients receiving neoadjuvant chemotherapy...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28621227/expression-of-epithelial-mesenchymal-transition-driver-brachyury-and-status-of-tumor-infiltrating-cd8-and-foxp3-lymphocytes-in-predicting-treatment-responses-to-neoadjuvant-chemotherapy-of-breast-cancer
#6
Kwan Ho Lee, Eun Young Kim, Yong Lai Park, Sung-Im Do, Seoung Wan Chae, Chan Heun Park
Brachyury has been characterized as a driver of epithelial-mesenchymal transition process which is regarded as an important mechanism of cancer cell invasion and metastatic progression. The status of tumor-infiltrating lymphocytes has been proposed to predict response to neoadjuvant chemotherapy in breast cancer. We investigated the clinical significance and value of tumor-infiltrating lymphocytes and brachyury as biomarkers to predict treatment responses to neoadjuvant chemotherapy in breast cancer. We also examined the correlation of the Neo-Bioscore with tumor-infiltrating lymphocytes and brachyury to indirectly predict long-term outcome...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28618304/breast-magnetic-resonance-imaging-use-in-patients-undergoing-neoadjuvant-chemotherapy-is-associated-with-less-mastectomies-in-large-ductal-cancers-but-not-in-lobular-cancers
#7
Ingeborg J H Vriens, Kristien Keymeulen, Marc B I Lobbes, Annelotte C M van Bommel, Grard A P Nieuwenhuijzen, Marjolein L Smidt, Liesbeth J Boersma, Thijs van Dalen, Carolien H Smorenburg, Henk Struikmans, Sabine Siesling, Adri C Voogd, Vivianne C G Tjan-Heijnen
BACKGROUND: To assess the impact of breast magnetic resonance imaging (MRI) use on surgical outcome per histological breast cancer subtype in patients treated with neoadjuvant chemotherapy. PATIENTS AND METHODS: All patients aged 18-70 years who underwent neoadjuvant chemotherapy for stage I-III invasive breast cancer in the Netherlands in the years 2011-2013 were identified from the Netherlands Cancer Registry. Patients with cT4 tumours were excluded from the analysis...
June 12, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28615970/changes-in-pulmonary-function-tests-in-breast-carcinoma-patients-treated-with-locoregional-post-mastectomy-radiotherapy-results-of-a-pilot-study
#8
Eyad Fawzi AlSaeed, Faisal Khalid Balaraj, Mutahir A Tunio
BACKGROUND: The aim of present pilot study was to evaluate the changes in pulmonary function tests (PFTs) after locoregional post-mastectomy radiotherapy (PMRT) in breast cancer patients. MATERIALS AND METHODS: Twenty consecutive patients with histopathologically confirmed breast carcinoma stages T1-T4, N1-N2, who were treated with modified radical mastectomy with neoadjuvant or adjuvant chemotherapy underwent PFTs, including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), forced expiratory flow at 50%, and peak expiratory flow rate, maximum mid expiratory flow (MMEF25-75), maximal oxygen consumption (VO2max), and carbon monoxide diffusing capacity (DLCO) before, at 30 days, and at 90 days after locoregional PMRT...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28612227/development-of-a-ki-67-based-clinical-trial-assay-for-neoadjuvant-endocrine-therapy-response-monitoring-in-breast-cancer
#9
Rodrigo Goncalves, Katherine DeSchryver, Cynthia Ma, Yu Tao, Jeremy Hoog, Maggie Cheang, Erika Crouch, Neha Dahiya, Souzan Sanati, Michael Barnes, Luis Otávio Zanatta Sarian, John Olson, Donald Craig Allred, Matthew J Ellis
PURPOSE: The recent publication of the ACOSOG Z1031 trial results demonstrated that Ki-67 proliferation marker-based neoadjuvant endocrine therapy response monitoring could be used for tailoring the use of adjuvant chemotherapy in ER+HER2-negative breast cancer patients. In this paper, we describe the development of the Ki-67 clinical trial assay used for this study. METHODS: Ki-67 assay assessment focused on reproducing a 2.7% Ki-67 cut-point (CP) required for calculating the Preoperative Endocrine Prognostic Index and a 10% CP for poor endocrine therapy response identification within the first month of neoadjuvant endocrine treatment...
June 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28611541/effectiveness-of-pertuzumab-trastuzumab-and-docetaxel-combination-neoadjuvant-chemotherapy-for-her2-positive-inflammatory-breast-cancer-a-case-report
#10
Yuji Yamashita, Yuko Tanaka, Seishi Kono, Meiko Nishimura, Toru Mukohara, Yukiko Morinaga, Shigeo Hara, Shintaro Takao
BACKGROUND: Inflammatory breast cancer (IBC) is the most aggressive form of primary breast cancer. CASE REPORT: A 40-year-old woman was referred to our hospital for evaluation of an induration in the right breast, suspected to be breast cancer. The tumor was diagnosed as estrogen receptor-negative, progesterone receptor-negative, HER2-positive, T4dN3cM0 stage IIIc IBC with axillary lymph node metastasis. Rather than surgical intervention, we chose a systemic treatment approach with pertuzumab, trastuzumab, and docetaxel (PTD) combination therapy which was shown to be effective for HER2-positive IBC in the NeoSphere trial...
March 2017: Breast Care
https://www.readbyqxmd.com/read/28611109/an-in-vivo-functional-screen-identifies-jnk-signaling-as-a-modulator-of-chemotherapeutic-response-in-breast-cancer
#11
Matthew Ashenden, Antoinette van Weverwijk, Nirupa Murugaesu, Antony Fearns, James Campbell, Qiong Gao, Marjan Iravani, Clare M Isacke
Chemotherapy remains the mainstay of treatment for advanced breast cancer, however, resistance is an inevitable event for the majority of patients with metastatic disease. Moreover, there is little information available to guide stratification of first line chemotherapy, crucial given the common development of multidrug resistance. Here we describe an in vivo screen to interrogate the response to anthracycline-based chemotherapy in a syngeneic metastatic breast cancer model, and identify JNK signaling as a key modulator of chemotherapy response...
June 13, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28608612/factors-impacting-the-accuracy-of-intra-operative-evaluation-of-sentinel-lymph-nodes-in-breast-cancer
#12
Catherine L Akay, Constance Albarracin, Tiffany Torstenson, Roland Bassett, Elizabeth A Mittendorf, Min Yi, Henry M Kuerer, Gildy V Babiera, Isabelle Bedrosian, Kelly K Hunt, Rosa F Hwang
Sentinel lymph node dissection (SLND) is a standard axillary staging technique in breast cancer and intraoperative sentinel lymph node (SLN) assessment is important for decision-making regarding additional treatment and reconstruction. This study was undertaken to investigate clinicopathologic factors impacting the accuracy of intraoperative SLN evaluation. Records of patients with clinically node-negative, invasive breast cancer who underwent SLND with frozen section intraoperative pathologic evaluation from 2004 to 2007 were reviewed...
June 13, 2017: Breast Journal
https://www.readbyqxmd.com/read/28604321/sentinel-lymph-node-biopsy-and-neoadjuvant-chemotherapy-in-the-management-of-early-breast-cancer-safety-considerations-and-timing
#13
Jenny Edge, Sarah Nietz
Over the last decades, breast cancer treatment has become more personalised. Treatment plans are based on the biology of the tumour rather than the stage. Consequently, neoadjuvant chemotherapy (NACT) is commonly the primary therapy for early breast cancer as well as locally advanced disease. Sentinel lymph node biopsy (SLNB) is standard axillary management for women with node-negative disease. This review looks at the relevant literature and gives guidance on the timing of SLNB when NACT is planned and evaluates the safety of performing an SLNB rather than an axillary clearance...
May 24, 2017: South African Medical Journal, Suid-Afrikaanse Tydskrif Vir Geneeskunde
https://www.readbyqxmd.com/read/28601382/long-term-follow-up-of-node-negative-breast-cancer-patients-evaluated-via-sentinel-node-biopsy-after-neoadjuvant-chemotherapy
#14
Hiroko Nogi, Ken Uchida, Rei Mimoto, Makiko Kamio, Hisashi Shioya, Yasuo Toriumi, Masafumii Suzuki, Eijiro Nagasaki, Tadashi Kobayashi, Hiroshi Takeyama
BACKGROUND: Sentinel node biopsy (SNB) is used to accurately assess axillary lymph node status in patients with node-negative breast cancer. However, its use after neoadjuvant chemotherapy (NAC) is controversial. We retrospectively assessed the usefulness of SNB after NAC by comparing axillary recurrence rates and other parameters in patients with clinically node-negative breast cancer who underwent SNB after NAC or without NAC. PATIENTS AND METHODS: At our hospital, 1179 patients with clinically node-negative breast cancer underwent SNB from April 2007 to December 2013...
May 8, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28600647/hybrid-18-f-fdg-pet-mri-might-improve-locoregional-staging-of-breast-cancer-patients-prior-to-neoadjuvant-chemotherapy
#15
Briete Goorts, Stefan Vöö, Thiemo J A van Nijnatten, Loes F S Kooreman, Maaike de Boer, Kristien B M I Keymeulen, Romy Aarnoutse, Joachim E Wildberger, Felix M Mottaghy, Marc B I Lobbes, Marjolein L Smidt
PURPOSE: Our purpose in this study was to assess the added clinical value of hybrid (18)F-FDG-PET/MRI compared to conventional imaging for locoregional staging in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). METHODS: In this prospective study, primary invasive cT2-4 N0 or cT1-4 N+ breast cancer patients undergoing NAC were included. A PET/MRI breast protocol was performed before treatment. MR images were evaluated by a breast radiologist, blinded for PET images...
June 10, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28596258/overuse-of-chest-ct-in-patients-with-stage-i-and-ii-breast-cancer-an-opportunity-to-increase-guidelines-compliance-at-an-nccn-member-institution
#16
Barbara Dull, Andrew Linkugel, Julie A Margenthaler, Amy E Cyr
Background: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) recommend that patients with clinical stage I/II breast cancer undergo advanced imaging for staging only when symptomatic. Regardless, many asymptomatic patients undergo chest CT. The goal of this study was to assess the use and results of chest CT in these patients at an NCCN Member Institution. Methods: Patients with breast cancer diagnosed between 1998 and 2012 were identified in a prospectively maintained database. All patients with clinical stage I/II disease who did not receive neoadjuvant chemotherapy were included...
June 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28592065/-impact-of-adjuvant-chemotherapy-on-the-prognosis-of-hormone-receptor-negative-breast-cancer-with-residual-lymph-node-disease-after-neoadjuvant-chemotherapy
#17
X Wang, Y J He, J F Li, Y T Xie, T F Wang, Z Q Fan, T Ouyang
Objective: To explore the influence of adjuvant chemotherapy on the prognosis of hormone receptor negative breast cancer with residual lymph node disease(RLND)after neoadjuvant chemotherapy. Methods: A total of 110 hormone receptor negative breast cancer patients treated with 4-8 cycles of neoadjuvant chemotherapy were respectively analysed between 2002 and 2012. Residual lymph node disease was comfirmed by subsequent radical mastectomy. Then all these patients were classified into two groups: patients treated with adjuvant chemotherapy(group A) and patients untreated with adjuvant chemotherapy(group B)...
May 30, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/28586961/long-term-results-of-a-highly-performing-conformal-electron-therapy-technique-for-chest-wall-irradiation-after-mastectomy
#18
Noemie Grellier Adedjouma, Marion Chevrier, Alain Fourquet, Emilie Costa, Haoping Xu, Frederique Berger, Francois Campana, Fatima Laki, Philippe Beuzeboc, Delphine Lefeuvre, Nathalie Fournier-Bidoz, Youlia M Kirova
PURPOSE: To evaluate locoregional control and survival after mastectomy, as well as toxicity, in patients irradiated by a previously described postmastectomy highly conformal electron beam radiation therapy technique (PMERT). METHODS AND MATERIALS: We included all women irradiated by postmastectomy electron beam radiation therapy for nonmetastatic breast cancer between 2007 and 2011 in our department. Acute and late toxicities were retrospectively assessed using Common Terminology Criteria for Adverse Events version 3...
May 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28583748/development-of-parp-inhibitors-in-gynecological-malignancies
#19
REVIEW
Yvonne L E Ang, David S P Tan
PARP inhibitors demonstrate synthetic lethality in tumors with BRCA1/2 mutations and other homologous recombination repair deficiencies by interfering with DNA repair and causing direct toxicity to DNA through PARP trapping. PARP inhibitors have been shown to be beneficial in the treatment of BRCA1/2-mutated ovarian cancers, which has led to a shift in the treatment paradigm of this disease. Further studies to establish the role of PARP inhibitors during earlier stages of treatment are ongoing. The use of PARP inhibitors in other cancers with homologous recombination repair deficiencies, such as breast cancer and prostate cancer, is gradually evolving as well, including their use in the neoadjuvant and adjuvant settings...
March 14, 2017: Current Problems in Cancer
https://www.readbyqxmd.com/read/28582336/breast-cancer-molecular-subtypes-and-chemotherapy-schedules-used-in-neoadjuvant-or-adjuvant-setting-may-show-different-effects-in-nipple-sparing-mastectomy
#20
Kadri Altundag
No abstract text is available yet for this article.
June 1, 2017: Plastic and Reconstructive Surgery
keyword
keyword
55442
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"